



May 8, 2025

Company: Ono Pharmaceutical Co., Ltd.
Representative: Toichi Takino
Representative Director, President and COO
(Securities Code: 4528 Prime market, TSE)
Contact: Ryuta Imura
Senior Director, Corporate Communications
(Phone: +81-6-6263-5670)

Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2025 and the Previous Fiscal Year

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino) today announced that there were differences in the non-consolidated financial results (Japanese standard) between the fiscal year ended March 2025 (April 1, 2024 to March 31, 2025) and the previous fiscal year.

1. Differences in the full-year non-consolidated financial results between the fiscal year ended March 2025 and the previous fiscal year

(Unit: Millions of yen, except basic earnings per share)

	Sales	Operating Profit	Ordinary Profit	Net Profit for the year	Basic earnings per share (yen)
Previous Results (A) (FY ended March 2024)	498,777	187,916	188,036	152,909	318.51
Actual Results (B) (FY ended March 2025)	451,756	114,709	112,263	102,415	218.02
Change (B-A)	(47,021)	(73,208)	(75,773)	(50,494)	—
Change (%)	(9.4)	(39.0)	(40.3)	(33.0)	—

2. Reasons for the differences

Sales totaled ¥451.8 billion, which was a decrease of ¥47.0 billion (9.4%) from the previous fiscal year (year on year) mainly due to the revision of the National Health Insurance (NHI) drug price for OPDIVO Intravenous Infusion for malignant tumors, a decrease in royalty revenue from Merck & Co., Inc., and others in line with a decrease in royalty rates, and the absence of the lump-sum income of ¥17.0 billion recorded in the same period of the previous year associated with the settlement of the litigation on patents with AstraZeneca UK Limited. In addition to the decrease of sales, mainly due to the recording of a sales milestone of ¥13.6 billion for FORXIGA Tablets as a expense, which are sold under a co-promotion agreement with AstraZeneca UK Limited, and expenses associated with the licensing agreement with LigaChem Biosciences, Inc., operating profit was ¥114.7 billion, a decrease of ¥73.2 billion (39.0%) year on year; ordinary profit was ¥112.3 billion, a decrease of ¥75.8 billion (40.3%) year on year; and net profit for the year was ¥102.4 billion, a decrease of ¥50.5 billion (33.0%).